Integrating genomics into clinical oncology: Ethical and social challenges from proponents of personalized medicine

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 2, 2014, Pages 187-192

  McGowan, Michelle L ^a   Settersten, Richard A ^b   Juengst, Eric T ^c   Fishman, Jennifer R ^d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Cancer genomics; Ethics; Genomic testing; Personalized medicine; Social implications; Targeted therapies

Indexed keywords

CONFIDENTIALITY; GENOMICS; HUMAN; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; MONITORING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW;

CANCER GENOMICS; ETHICS; GENOMIC TESTING; PERSONALIZED MEDICINE; SOCIAL IMPLICATIONS; TARGETED THERAPIES;

CONFIDENTIALITY; DELIVERY OF HEALTH CARE; DISCLOSURE; GENETIC PRIVACY; GENETIC TESTING; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; INFORMED CONSENT; INTERVIEWS AS TOPIC; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 84892508175     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.10.009     Document Type: Review

References (26)

1. Juengst E.T., Settersten R.A., Fishman J.R., McGowan M.L. After the revolution? Ethical and social challenges in personalized genomic medicine. Pers Med 2012, 9:429-439.
2. Hamburg M.A., Collins F.S. The path to personalized medicine. N Engl J Med 2010, 363:301-304.
3. Raman G, Wallace B, Patel K, et al. Update on horizon scans of genetic tests currently available for clinical use in cancers. In. Center for Medicare and Medicaid Services; 2011.
4. Schilsky R.L. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 2010, 9:363-366.
5. Weldon C.B., Trosman J.R., Gradishar W.J., et al. Barriers to the use of personalized medicine in breast cancer. J Oncol Pract 2012, 8:e24-e31.
6. Miller F.A., Krueger P., Christensen R.J., et al. Postal survey of physicians and laboratories: practices and perceptions of molecular oncology testing. BMC Health Serv Res 2009, 9:131.
7. Gooding H.C., Linnenbringer E.L., Burack J., et al. Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk. Patient Educ Couns 2006, 64:259-267.
8. Cassidy M.R., Roberts J.S., Bird T.D., et al. Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease. Alzheimers Dement 2008, 4:406-413.
9. Bombard Y., Palin J., Friedman J.M., et al. Beyond the patient: the broader impact of genetic discrimination among individuals at risk of Huntington disease. Am J Med Genet B 2012, 159B:217-226.
10. Merriam S. Qualitative Research: A Guide to Design and Implementation 2009, Jossey-Bass, San Francisco.
11. McLellan E., MacQueen K.M., Neidig J.L. Beyond the qualitative interview: data preparation and transcription. Field Methods 2003, 15:63-84.
12. Braun V., Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006, 3:77-101.
13. Clayton E.W. Ethical, legal, and social implications of genomic medicine. N Engl J Med 2003, 349:562-569.
14. Anderlik M.R., Rothstein M.A. Privacy and confidentiality of genetic information: what rules for the new science?. Annu Rev Genomics Hum Genet 2001, 2:401-433.
15. Storm C., Agarwal R., Offit K. Ethical and legal implications of cancer genetic testing: do physicians have a duty to warn patients' relatives about possible genetic risks?. J Oncol Pract 2008, 4:229-230.
16. Green R.C., Berg J.S., Grody W.W., et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013, 15:565-574.
17. Lolkema M.P., Gadellaa-van Hooijdonk C.G., Bredenoord A.L., et al. Ethical, legal, and counseling challenges surrounding the return of genetic results in oncology. J Clin Oncol 2013, 31:1842-1848.
18. Sharp R.R. Downsizing genomic medicine: approaching the ethical complexity of whole-genome sequencing by starting small. Genet Med 2011, 13:191-194.
19. Manolio T.A., Chisholm R.L., Ozenberger B., et al. Implementing genomic medicine in the clinic: the future is here. Genet Med 2013, 15:258-267.
20. Ayuso C., Millan J.M., Mancheno M., Dal-Re R. Informed consent for whole-genome sequencing studies in the clinical setting. Proposed recommendations on essential content and process. Eur J Hum Genet 2013, 21:1054-1059.
21. Thorogood A., Knoppers B.M., Dondorp W.J., de Wert G. Whole-genome sequencing and the physician. Clin Genet 2012, 81:511-513.
22. McGowan M.L., Glinka A., Highland J., et al. Genetics patients' perspectives on clinical genomic testing. Pers Med 2013, 10:339-347.
23. Feero W. WCVDL. The economics of genomic medicine: insights from the iom roundtable on translating genomic-based research for health. J Am Med Assoc 2013, 309:1235-1236.
24. Case Comprehensive Cancer Center. Implementing proper use of genomic tests to select therapeutics open drug policy forum. In. Case Western Reserve University; 2013.
25. Fleck L.M. Pharmacogenomics and personalized medicine: wicked problems, ragged edges and ethical precipices. N Biotechnol 2012, 29:757-768.
26. McClellan K.A., Avard D., Simard J., Knoppers B.M. Personalized medicine and access to health care: potential for inequitable access?. Eur J Hum Genet 2013, 21:143-147.